Human Biodistribution and Radiation Dosimetry for the Tau Tracer [F]Florzolotau in Healthy Subjects

Overview

Journal EJNMMI Radiopharm Chem

Date 2024 Apr 2

PMID 38563872

Authors

Kun-Ju Lin

Shao-Yi Huang

Kuo-Lun Huang

Chin-Chang Huang

Ing-Tsung Hsiao

Affiliations

Soon will be listed here.

Abstract

Background: Tau pathology plays a crucial role in neurodegeneration diseases including Alzheimer's disease (AD) and non-AD diseases such as progressive supranuclear palsy. Tau positron emission tomography (PET) is an in-vivo and non-invasive medical imaging technique for detecting and visualizing tau deposition within a human brain. In this work, we aim to investigate the biodistribution of the dosimetry in the whole body and various organs for the [F]Florzolotau tau-PET tracer. A total of 12 healthy controls (HCs) were enrolled at Chang Gung Memorial Hospital. All subjects were injected with approximately 379.03 ± 7.03 MBq of [F]Florzolotau intravenously, and a whole-body PET/CT scan was performed for each subject. For image processing, the VOI for each organ was delineated manually by using the PMOD 3.7 software. Then, the time-activity curve of each organ was acquired by optimally fitting an exponential uptake and clearance model using the least squares method implemented in OLINDA/EXM 2.1 software. The absorbed dose for each target organ and the effective dose were finally calculated.

Results: From the biodistribution results, the elimination of [F]Florzolotau is observed mainly from the liver to the intestine and partially through the kidneys. The highest organ-absorbed dose occurred in the right colon wall (255.83 μSv/MBq), and then in the small intestine (218.67 μSv/MBq), gallbladder wall (151.42 μSv/MBq), left colon wall (93.31 μSv/MBq), and liver (84.15 μSv/MBq). Based on the ICRP103, the final computed effective dose was 34.9 μSv/MBq with CV of 10.07%.

Conclusions: The biodistribution study of [F]Florzolotau demonstrated that the excretion of [F]Florzolotau are mainly through the hepatobiliary and gastrointestinal pathways. Therefore, a routine injection of 370 MBq or 185 MBq of [F]Florzolotau leads to an estimated effective dose of 12.92 or 6.46 mSv, and as a result, the radiation exposure to the whole-body and each organ remains within acceptable limits and adheres to established constraints.

Trial Registration: Retrospectively Registered at Clinicaltrials.gov (NCT03625128) on 12 July, 2018, https://clinicaltrials.gov/study/NCT03625128 .

Citing Articles

Patterns of Tau pathology in patients with anti-IgLON5 disease visualized by Florzolotau (18F) PET.

Fan S, Jia C, Liang M, Ren H, Zhang T, Li Q J Neurol. 2025; 272(2):115.

PMID: 39812840 DOI: 10.1007/s00415-024-12874-4.

References

Li L, Liu F, Li M, Lu J, Sun Y, Liang X . Clinical Utility of F-APN-1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy. Mov Disord. 2021; 36(10):2314-2323. DOI: 10.1002/mds.28672. View

Mueller A, Bullich S, Barret O, Madonia J, Berndt M, Papin C . Tau PET imaging with F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study. J Nucl Med. 2019; 61(6):911-919. PMC: 7262222. DOI: 10.2967/jnumed.119.236224. View

Yousefzadeh-Nowshahr E, Winter G, Bohn P, Kneer K, von Arnim C, Otto M . Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting. PLoS One. 2022; 17(4):e0266906. PMC: 9045369. DOI: 10.1371/journal.pone.0266906. View

Hachinski V . Dementia: new vistas and opportunities. Neurol Sci. 2019; 40(4):763-767. DOI: 10.1007/s10072-019-3714-1. View

Binette A, Franzmeier N, Spotorno N, Ewers M, Brendel M, Biel D . Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease. Nat Commun. 2022; 13(1):6635. PMC: 9636262. DOI: 10.1038/s41467-022-34129-4. View

. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP. 2003; 32(3-4):5-265. View

. Human alimentary tract model for radiological protection. ICRP Publication 100. A report of The International Commission on Radiological Protection. Ann ICRP. 2006; 36(1-2):25-327, iii. DOI: 10.1016/j.icrp.2006.03.004. View

Weng C, Hsiao I, Yang Q, Yao C, Tai C, Wu M . Characterization of F-PM-PBB3 (F-APN-1607) Uptake in the rTg4510 Mouse Model of Tauopathy. Molecules. 2020; 25(7). PMC: 7181044. DOI: 10.3390/molecules25071750. View

Stabin M, Wendt 3rd R, Flux G . RADAR Guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals, Part 1-Collection of Data for Radiopharmaceutical Dosimetry. J Nucl Med. 2021; 63(2):316-322. DOI: 10.2967/jnumed.120.259200. View

10.

Miyamoto M, Okuyama C, Kagawa S, Kusano K, Takahashi M, Takahata K . Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects. Ann Nucl Med. 2023; 37(5):300-309. PMC: 10129982. DOI: 10.1007/s12149-023-01828-x. View

11.

Stabin M, Siegel J . RADAR Dose Estimate Report: A Compendium of Radiopharmaceutical Dose Estimates Based on OLINDA/EXM Version 2.0. J Nucl Med. 2017; 59(1):154-160. DOI: 10.2967/jnumed.117.196261. View

12.

Hsiao I, Lin K, Huang K, Huang C, Chen H, Wey S . Biodistribution and Radiation Dosimetry for the Tau Tracer F-THK-5351 in Healthy Human Subjects. J Nucl Med. 2017; 58(9):1498-1503. DOI: 10.2967/jnumed.116.189126. View

13.

Sengupta U, Kayed R . Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Prog Neurobiol. 2022; 214:102270. DOI: 10.1016/j.pneurobio.2022.102270. View

14.

Tang Y, Li L, Hu T, Jiao F, Han L, Li S . In Vivo F-Florzolotau Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia. Mov Disord. 2022; 38(1):147-152. DOI: 10.1002/mds.29273. View

15.

Gale S, Acar D, Daffner K . Dementia. Am J Med. 2018; 131(10):1161-1169. DOI: 10.1016/j.amjmed.2018.01.022. View

16.

Liu F, Lu J, Li X, Liang X, Jiao F, Ge J . F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging. 2023; 50(5):1395-1405. PMC: 10027831. DOI: 10.1007/s00259-022-06104-0. View

17.

Hanseeuw B, Betensky R, Jacobs H, Schultz A, Sepulcre J, Becker J . Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurol. 2019; 76(8):915-924. PMC: 6547132. DOI: 10.1001/jamaneurol.2019.1424. View

18.

Choi J, Lyoo C, Lee J, Cho H, Kim K, Kim J . Human Radiation Dosimetry of [(18)F]AV-1451(T807) to Detect Tau Pathology. Mol Imaging Biol. 2016; 18(4):479-82. DOI: 10.1007/s11307-015-0924-7. View

19.

Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J . Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013; 79(6):1094-108. PMC: 3809845. DOI: 10.1016/j.neuron.2013.07.037. View

20.

Maeda Y, Kudomi N, Yamamoto H, Yamamoto Y, Nishiyama Y . Image accuracy and quality test in rate constant depending on reconstruction algorithms with and without incorporating PSF and TOF in PET imaging. Ann Nucl Med. 2015; 29(7):561-9. DOI: 10.1007/s12149-015-0979-1. View